Equity · Healthcare
RXRX
Recursion Pharmaceuticals, Inc. · NasdaqGS
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for RXRX to draw a line in its place.
The chart above plots the price of RXRX over the range selected — one day to the full history — drawn by TradingView from their own data.
Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 21, 2026
RXRX insider trades
RXRX has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 17 August 2026.
Showing the 12 most recent of 37 open-market trades in this window. The figures above count all of them.
Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
Showing the 12 most recent of 76 compensation filings in this window. The figures above count all of them.
RXRX reported financials
RXRX reported revenue of $74.7M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$644.8M.
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
RXRX earnings
no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
RXRX institutional holders
10 of the 45 institutional funds we track reported a RXRX position for the quarter ended 30 Jun 2026 — a combined $194.5M; the latest of those filings landed 14 Aug 2026.
Source: SEC EDGAR 13F filings